Invenra Inc. announced a strategic collaboration with Catalent. The collaboration will harness the combined expertise and proprietary technologies of Invenra and Catalent to co-d discover novel bispecific antibody-drug conjugates. Both companies share a commitment to developing novel therapeutic solutions with the potential to make a meaningful impact in the lives of patients.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
55 USD | -0.67% | -1.43% | +22.41% |
May. 16 | Argus Downgrades Catalent to Sell From Buy | MT |
May. 14 | Novo Nordisk Selling $5 Billion in Bonds to Back Catalent Deal | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+22.41% | 9.95B | |
+34.35% | 705B | |
+31.28% | 583B | |
-3.49% | 364B | |
+20.15% | 332B | |
+6.19% | 291B | |
+14.94% | 238B | |
-3.68% | 210B | |
+10.06% | 209B | |
+9.21% | 169B |
- Stock Market
- Equities
- CTLT Stock
- News Catalent, Inc.
- Invenra Inc. Announces Strategic Collaboration with Catalent to Co-Discover Novel Bispecific ADCs